- |||||||||| BNT121 / BioNTech, Roche, RBL001/RBL002 / BioNTech
Trial completion, Metastases: IVAC MUTANOME Phase I Clinical Trial (clinicaltrials.gov) - Jan 15, 2020
P1, N=15, Completed,
Active, not recruiting --> Completed
- |||||||||| BNT121 / BioNTech, Roche, RBL001/RBL002 / BioNTech
Trial completion date, Metastases: IVAC MUTANOME Phase I Clinical Trial (clinicaltrials.gov) - Aug 5, 2019
P1, N=15, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Mar 2019 --> Oct 2019
- |||||||||| BNT121 / BioNTech, Roche, RBL001/RBL002 / BioNTech
Trial completion date, Trial primary completion date, Metastases: IVAC MUTANOME Phase I Clinical Trial (clinicaltrials.gov) - Nov 15, 2018
P1, N=15, Active, not recruiting,
Trial completion date: Mar 2019 --> Oct 2019 Trial completion date: Apr 2018 --> Mar 2019 | Trial primary completion date: Feb 2016 --> Feb 2017
- |||||||||| BNT121 / BioNTech, Roche, RBL001/RBL002 / BioNTech
Trial primary completion date, Metastases: IVAC MUTANOME Phase I Clinical Trial (clinicaltrials.gov) - Sep 28, 2016
P1, N=15, Active, not recruiting,
Trial completion date: Apr 2018 --> Mar 2019 | Trial primary completion date: Feb 2016 --> Feb 2017 Trial primary completion date: May 2016 --> Feb 2016
- |||||||||| BNT121 / BioNTech, Roche, RBL001/RBL002 / BioNTech
Enrollment closed, Trial primary completion date, Metastases: IVAC MUTANOME Phase I Clinical Trial (clinicaltrials.gov) - Jan 20, 2016
P1, N=15, Active, not recruiting,
Trial primary completion date: May 2016 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> May 2016
- |||||||||| RBL001/RBL002 / BioNTech
Trial completion, Enrollment change, Metastases: MERIT: RBL001/RBL002 Phase I Clinical Trial (clinicaltrials.gov) - Jul 22, 2015
P1, N=29, Completed,
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> May 2016 Active, not recruiting --> Completed | N=21 --> 29
- |||||||||| RBL001/RBL002 / BioNTech
Enrollment closed, Trial primary completion date, Metastases: MERIT: RBL001/RBL002 Phase I Clinical Trial (clinicaltrials.gov) - Jan 28, 2015
P1, N=21, Active, not recruiting,
Active, not recruiting --> Completed | N=21 --> 29 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Apr 2015
- |||||||||| BNT121 / BioNTech, Roche, RBL001/RBL002 / BioNTech
New P1 trial, Metastases: IVAC MUTANOME Phase I Clinical Trial (clinicaltrials.gov) - Jan 12, 2014
P1, N=15, Recruiting,
|
